Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

Novavax, Inc. (NVAX) on Thursday announced preclinical data demonstrating that the company’s H5N1 bird flu vaccine candidate induced robust immune responses in nonhuman primates. H5N1 is a highly ...

Investing.com -- Novavax (NASDAQ: NVAX) stock rose 5% after the company announced positive preclinical results for its H5N1 avian influenza vaccine candidate, showing strong immune responses in ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

The Novavax vaccine targets the same XBB.1.5 variant as the other two vaccines. That variant was the dominant one in the U.S. earlier this year when the FDA had to choose the makeup of this fall's ...

And the Novavax Covid-19 vaccine that just got emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) is certainly new. It’s new in that it’s not completely new.

Novavax, a small biotech company in Maryland, garnered attention June 18 when it announced its vaccine candidate is more than 90% effective overall and 100% effective at preventing moderate to ...

The Novavax vaccine would be authorized for use in adults only in two doses. The company submitted a request, which the FDA is considering, to provide the same vaccine as a booster dose.

Novavax COVID vaccine will still save lives, experts say, even with limited supply. There are still more than 26 million American adults who are unvaccinated.

Novavax’s study involved nearly 30,000 people ages 18 and up in the U.S. and Mexico. Two-thirds received two doses of the vaccine, three weeks apart, and the rest got dummy shots.